title: Thrombocytopoiesis in normal and sublethally irradiated dogs: response to human interleukin-6.
abstract: The response of megakaryocytes and platelets to the administration of recombinant human interleukin-6 (IL-6) was investigated in normal and sublethally irradiated dogs. IL-6 was administered for 2 weeks at doses of 10 to 160 micrograms/kg/d to normal animals to assess dose-response and toxicity. Subsequently, 40, 80, or 160 micrograms/kg/d for 2 weeks was administered to animals treated with 200 cG total body irradiation. Analysis of normal dogs showed a significant increment in the platelet count detectable approximately 11 days after initiation of IL-6 at all administered doses. Large platelets greater than 6.3 microns in diameter were observed 1 day after beginning IL-6, progressively increasing to as many as 19.1% of the total circulating platelets by day 10. The ploidy distribution of the marrow megakaryocytes did not differ from the normal at doses of less than or equal to 80 micrograms/kg/d, but at 160 micrograms/kg/d, a shift toward higher ploidy cells was noted. No change in total white count was noted; however, a decrease in hematocrit was seen at all doses. In the irradiated animals, the platelet count recovered earlier in the IL-6-treated dogs than in the controls, but no consistent change in the ploidy distribution was observed irrespective of dose. Large platelets were also noted in the treated animals, comprising up to 6.9% of the total platelet count. Fibrinogen levels were elevated to greater than 4 times normal. A significant decrease in hematocrit was seen in all animals, while no consistent change was noted in the white count. Elevations in serum cholesterol, triglycerides, and alkaline phosphatase, together with a decline in serum albumin were observed in all the treated animals (both normal and irradiated), but clinical symptoms were observed only in the dogs receiving greater than or equal to 80 micrograms/kg/d. The data show that IL-6 alone is capable of enhancing platelet recovery in dogs with bone marrow suppression.
authors.affiliation: Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City 73190.
authors.forename: S A
authors.initials: SA
authors.lastname: Burstein
authors.forename: T
authors.initials: T
authors.lastname: Downs
authors.forename: P
authors.initials: P
authors.lastname: Friese
authors.forename: S
authors.initials: S
authors.lastname: Lynam
authors.forename: S
authors.initials: S
authors.lastname: Anderson
authors.forename: J
authors.initials: J
authors.lastname: Henthorn
authors.forename: R B
authors.initials: RB
authors.lastname: Epstein
authors.forename: K
authors.initials: K
authors.lastname: Savage
mesh_terms: D000818:Animals; D001792:Blood Platelets / Q000166:cytology / Q000187:drug effects* / Q000528:radiation effects; D001853:Bone Marrow / Q000187:drug effects / Q000528:radiation effects; D001854:Bone Marrow Cells; D004285:Dogs; D005340:Fibrinogen / Q000378:metabolism; D006410:Hematopoiesis / Q000187:drug effects* / Q000528:radiation effects; D015850:Interleukin-6 / Q000097:blood / Q000494:pharmacology*; D007700:Kinetics; D010976:Platelet Count / Q000187:drug effects* / Q000528:radiation effects; D011003:Ploidies; D011994:Recombinant Proteins / Q000494:pharmacology; D013997:Time Factors; D014916:Whole-Body Irradiation
chemical_list: D015850:Interleukin-6; D011994:Recombinant Proteins; D005340:Fibrinogen